|
|
| Research article summary (published 28 Jul 2008): |
Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease.
Full Abstract
OBJECTIVE: The substantial weight loss in Parkinson's patients may be related to direct influences of levodopa treatment on fat mobilization/oxidation. We assessed systemic and local metabolic responses to levodopa/benserazide in patients with idiopathic Parkinson's disease. METHODS: We studied 10 Parkinson's disease patients and examined adipose tissue and skeletal muscle metabolism directly with microdialysis. We monitored dialysate concentrations of ethanol, glucose, lactate, pyruvate, and glycerol to assess tissue blood flow and metabolism before and after levodopa/benserazide intake. We also conducted in vitro studies on adipocytes from healthy women. RESULTS: Levodopa/benserazide increased serum levodopa, 3,4-dihydroxyphenylacetic acid (DOPAC), and norepinephrine (P < 0.01). Serum adipose tissue and skeletal muscle glycerol did not change or decreased. Adipose tissue glycerol was inversely correlated with serum levodopa concentrations (P < 0.05). In isolated adipocytes, levodopa attenuated isoproterenol-induced glycerol release (P < 0.05). CONCLUSION: Levodopa/benserazide elicits pronounced metabolic changes in both adipose tissue and skeletal muscle with a switch from lipid to carbohydrate metabolism. In adipose tissue, levodopa/benserazide failed to activate lipolysis. Therefore, we suggest that levodopa/benserazide does not induce fat wasting through direct and acute influences on adipose tissue metabolism.
Author information
Author/s: Adams, Frauke (F); Boschmann, Michael (M); Lobsien, Elmar (E); Kupsch, Andreas (A); Lipp, Axel (A); Franke, Gabriele (G); Leisse, Marie Charlotte (MC); Janke, Juergen (J); Gottschalk, Simone (S); Spranger, Joachim (J); Jordan, Jens (J);
Affiliation: Experimental and Clinical Research Center, A Cooperation with Max Delbrueck Center for Molecular Medicine, Charité Campus Buch, and HELIOS Klinikum, Berlin, Germany. Frauke.Adams(-atsign-)charite.de
Journal and publication information
Publication Type: Journal Article
Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol), published in Germany. (Language: eng)
Reference: 2008-Sep; vol 64 (issue 9) : pp 863-70
Dates: Created 2008/09/02; Completed 2008/12/09;
PMID: 18665357, status: MEDLINE (last retrieved date: 2/18/2009)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MeSH Headings (categories) shown below.
Note: Bold headings indicate primary MeSH headings or qualifiers.
Associated Chemicals: Antiparkinson Agents (0) ; Levodopa (0) ; Benserazide (322-35-0) ; Glycerol (56-81-5) ; Isoproterenol (7683-59-2)Related articles
These are the most related articles currently in our database:
- Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
30 May 2003 - Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
30 Jul 2006 - COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's disease.
30 Dec 1998 - Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
10 Jun 2006 - Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.
30 Dec 1998 - Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
30 Dec 2001 - [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)]
30 Mar 1979 - New L-dopa codrugs as potential antiparkinson agents.
29 Jun 2008 - Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.
2 Aug 2004 - Beta-adrenergic regulation of amine precursor amino acid transport across the blood-brain barrier.
12 May 1992
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a larger map of 100+ related articles.